The clinical management of HCV in the HIV-infected patient

Antiviral Therapy

Volumn 20, Issue 5, 2015, Pages 457-467

  Norton, Brianna ^a   Naggie, Susanna ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; DACLATASVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; MARAVIROC; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; RILPIVIRINE; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT;

ANEMIA; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELASTOGRAPHY; END STAGE LIVER DISEASE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICAL HISTORY; MIXED INFECTION; NON INVASIVE MEASUREMENT; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; REVIEW; SCREENING TEST; SEROLOGY; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION; COINFECTION; COMBINATION DRUG THERAPY; COMPLICATION; DISEASE COURSE; DRUG INTERACTION; HEPATITIS C, CHRONIC; HIV INFECTIONS; LIVER; MORTALITY; PATHOLOGY; TRANSMISSION; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; COINFECTION; DISEASE PROGRESSION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELASTICITY IMAGING TECHNIQUES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; VIRAL LOAD;

EID: 84947217702     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2910     Document Type: Review

References (102)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1:74-81.
2. Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 2010; 8:1002-1012.
3. Aids.gov. Global statistics. Department of Health and Human Services. 2012. (Accessed 19 May 2014.) Available from http://aids.gov/hiv-aids-basics/hiv-aids-101/globalstatistics/index.html
4. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS 2014; 28:1181-1191.
5. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241-248.
6. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57:2164-2170.
7. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Digest Liver Dis 2011 43:66-72.
8. Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198:1337-1344.
9. Witt MD, Seaberg EC, Darilay A, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis 2013; 57:77-84.
10. Matser A, Vanhommerig J, Schim van der Loeff MF, et al. HIV-infected men who have sex with men who identify themselves as belonging to subcultures are at increased risk for hepatitis C infection. PLoS ONE 2013; 8:e57740.
11. Leruez-Ville M, Kunstmann JM, De Almeida M, Rouzioux C, Chaix ML. Detection of hepatitis C virus in the semen of infected men. Lancet 2000; 356:42-43.
12. Manavi M, Watkins-Riedel T, Kucera E, Czerwenka K, Hofmann H. Evidence of hepatitis C virus in cervical smears. J Infect 1999; 38:60-61.
13. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991; 115:764-768.
14. Hallam NF, Fletcher ML, Read SJ, Majid AM, Kurtz JB, Rizza CR. Low risk of sexual transmission of hepatitis C virus. J Med Virol 1993; 40:251-253.
15. Bresters D, Mauser-Bunschoten EP, Reesink HW, et al. Sexual transmission of hepatitis C virus. Lancet 1993; 342:210-211.
16. Hershow RC, Kalish LA, Sha B, Till M, Cohen M. Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission. Sex Transm Dis 1998; 25:527-532.
17. Frederick T, Burian P, Terrault N, et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS 2009; 23:915-923.
18. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore-an analysis of 309 sex partnerships. J Infect Dis 1995; 171:768-775.
19. Salleras L, Bruguera M, Vidal J, et al. Importance of sexual transmission of hepatitis C virus in seropositive pregnant women: a case-control study. J Med Virol 1997; 52:164-167.
20. Mele A, Tosti ME, Marzolini A, et al. Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis. SEIEVA collaborating Group. J Viral Hepat 2000; 7:30-35.
21. Feldman JG, Minkoff H, Landesman S, Dehovitz J. Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner city women. Sex Transm Dis 2000; 27:338-342.
22. Marx MA, Murugavel KG, Tarwater PM, et al. Association of hepatitis C virus infection with sexual exposure in southern India. Clin Infect Dis 2003; 37:514-520.
23. Götz HM, van Doornum G, Niesters HG, den Hollander JG, Thio HB, de Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men-results from contact tracing and public health implications. AIDS 2005; 19:969-974.
24. Serpaggi J, Chaix ML, Batisse D, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20:233-240.
25. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21:983-991.
26. Montoya-Ferrer A, Fierer DS, Alvarez-Alvarez B, de Gorgolas M, Fernandez-Guerrero ML. Acute hepatitis C outbreak among HIV-infected men, Madrid, Spain. Emerg Infect Dis 2011; 17:1560-1562.
27. Matthews GV, Hellard M, Kaldor J, Lloyd A, Dore GJ. Further evidence of HCV sexual transmission among HIVpositive men who have sex with men: response to Danta et al. AIDS 2007; 21:2112-2113.
28. Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41:31-36.
29. Fierer DSFS, Uriel AJ. Characterization of an outbreak of acute HCV infection in HIV-infected men in New York City. 16th Conference on Retroviruses and Opportunistic Infections. DD MM 2009, Montreal, QC, Canada. Abstract 802.
30. van de Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIVpositive men who have sex with men. Gastroenterology 2009; 136:1609-1617.
31. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009; 23:F1-F7.
32. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommendations and Reports 2010; 59 (RR-12):1-110.
33. European AIDS Clinical Society Guidelines. 2014. (Accessed 18 September 2014.) Available from http://www.eacsociety.org/Portals/0/140601-EACS EN7.02.pdf
34. British HIV Association Guidelines. 2012. (Accessed 18 September 2014.) Available from http://www.bhiva.org/guidelines.aspx
35. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-378.
36. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058.
37. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
38. Bierhoff E, Fischer HP, Willsch E, et al. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Archiv 1997; 430:271-277.
39. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
40. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22:1979-1991.
41. Bräu N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55.
42. Pascual-Pareja JF, Caminoa A, Larrauri C, et al. HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. AIDS 2009; 23:971-975.
43. Sterling RK, Wegelin JA, Smith PG, et al. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol 2010; 8:1070-1076.
44. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100:56-63.
45. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Intl 2011; 5:625-634.
46. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46:912-921.
47. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102:2589-2600.
48. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated metaanalysis. Hepatology 2011; 53:726-736.
49. Shaheen AA, Myers RP. Systematic review and metaanalysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials 2008; 9:43-51.
50. FDA. Echosens' FibroScan System: 501(k) Summary. FDA. 2013 (Accessed 19 May 2014.) Available from http://www.accessdata.fda.gov/cdrh-docs/pdf12/k123806.pdf
51. de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
52. Vergara S, Macias J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45:969-974.
53. Sánchez-Conde M, Miralles P, Bellon JM, et al. Use of transient elastography (FibroScan(R)) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients. J Viral Hepat 2011; 18:685-691.
54. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol 2012; 56:564-570.
55. Arena U, Vizzutti F, Abraldes JG, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57:1288-1293.
56. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49:1017-1044.
57. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-2618.
58. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterol 2013; 144:1450-1455e2.
59. Zeuzem S, Mensa FJ. Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study. Hepatology 2013; 58:1516.
60. Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, et al. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 2009; 63:1256-1263.
61. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509-516e1.
62. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-2593.
63. Berenguer J, Zamora FX, Carrero A, et al. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr 2014; 66:280-287.
64. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
65. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
66. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
67. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
68. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
69. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. US Department of Health and Human Services. 2014. (Accessed 19 May 2014.) Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
70. Summary of product characteristics-Incivo. European Medicines Agency. 2011. (Accessed 19 May 2014.) Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002313/WC500115529.pdf
71. Olysio (simeprevir). Highlights of prescribing information. Janssen Therapeutics, Titusville, NJ. 2014. (Accessed 18 September 2014.) Available from https://www.olysio.com/shared/product/olysio/prescribing-information.pdf
72. SOVALDI. (sofosbuvir). Highlights of prescribing information. Gilead Sciences, Foster City, CA, USA. 2013. (Accessed 18 September 2014.) Available from https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf
73. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58:1918-1929.
74. Dieterich DRJ, Orkin C, Gutierrez F, et al. Simeprevir (TMC435) plus pegylated interferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: primary analysis of the TMC435-C212 study. 14th European AIDS Conference. 16-19 October 2013, Brussels, Belgium. Abstract PS9/5.
75. Dieterich DRJ, Orkin C, Gutierrez F, et al. Simeprevir plus pegIFN/ribavirin in HCV genotype-1/HIV-1 co-infection (Study C212). 21st Conference on Retroviruses and Opportunistic Infections. 3-6 March 2014, Boston, MA, USA. Abstract 24.
76. Ouwerkerk-Mahadevan SSA, Peeters M, Beumont-Mauviel M. Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus NS3/4A protease inhibitor. 14th European AIDS Conference. 16-19 October 2013, Brussels, Belgium. Abstract PE/10/7.
77. Infectious Diseases Society of America/American Association for the Study of the Liver. Recommendations for testing, managing, and treating hepatitis C. 2014. (Accessed 19 May 2014.) Available from http://www.hcvguidelines.org/
78. Mathias A, Cornpropst M, Clemons D, Denning J, Symonds W. No clinically significant pharmacokinetic drugdrug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporing A or tacrolimus in healthy volunteers. Hepatology 2012; 56 Supp 4:1063A-1064A.
79. Kirby B MA, Rossi S, Moyer C, et al. No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. Hepatology 2012; 56 Suppl 4:1067A.
80. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887.
81. Rodriguez-Torres MR-OJ, Gaggar A, Shen G, et al. Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naive genotype 1-4 HCV-infected patients who are coinfected with HIV. ID Week. 2-6 October 2013, San Francisco, CA, USA. Abstract 714.
82. Naggie SSM, Lalezari J, Fessel J, Mounzer K, Shuhart M. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). 21st Conference on Retroviruses and Opportunistic Infections. 3-6 March 2014, Boston, MA, USA. Abstract 26.
83. Mascolini M. High SVR12 with sofosbuvir/ribavirin in HCV/HIV-coinfected: PHOTON-2. 20th International AIDS Conference. 20-25 July 2014, Melbourne, Australia. Abstract MOAB0105LB.
84. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
85. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-1877.
86. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, Phase 2 trial. Lancet Infect Dis 2013; 13:401-408.
87. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756-1765.
88. OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection. 2014. (Accepted 18 September 2014.) Available from https://www.jnj.com/news/all/OLYSIO-simeprevir-receives-marketing-authorisationin-the-European-Union-for-the-treatment-of-adults-withhepatitis-C-genotype-1-and-4-infection
89. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898.
90. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-1493.
91. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-1888.
92. Osinusi A, Townsend K, Nelson A, et al. Use of sofosbuvir/ledipasvir fixed dose combination for treatment of HCV genotype-1 in patients coinfected with HIV. 49th European Association for the Study of the Liver International Liver Congress (EASL). 9-13 April 2014, London, UK. Abstract 014.
93. German P, Pang P, West S, Han L, Sajwani K, Mathias A (editors). Drug interactions between direct-acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. 19-21 May 2014, Washington, DC, USA. Abstract 0-06.
94. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983-1992.
95. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-1603.
96. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604-1614.
97. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-1982.
98. Sulkowski MEJ, Wyles D, Trinh R, et al. TURQUOISE-I: safety and efficacy of ABT-450/r/ombitasvir, dasabuvir, and ribavirin in patients co-infected with hepatitis C and HIV-1. 20th International AIDS Conference. 20-25 July 2014, Melbourne, Australia. Abstract MOAB0104LB.
99. Phase III HIV/HCV co-infection daclatasvir (DCV) + sofosbuvir (SOF) (ALLY 2). 2014. (Accessed 19 May 2014.) Available from http://clinicaltrials.gov/show/NCT02032888
100. Efficacy and safety study of pegylated interferon lambda-1a with ribavirin and daclatasvir, to treat naive subjects with chronic HCV genotypes 1, 2, 3 and 4 who are co-infected with HIV (DIMENSION). 2013. (Accessed 19 May 2014.) Available from http://clinicaltrials.gov/show/NCT01866930
101. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013; 18:931-940.
102. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-221.